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Highlights 14 
 This retrospective records study investigated 116 dogs diagnosed with 15 
meningoencephalitis of unknown aetiology (MUA). 16 
 Thirty of 114 (26%) of dogs died within 1 week of diagnosis of MUA. 17 
 Negative prognostic factors were decreased mentation and seizures at 18 
presentation. 19 
 An increased neutrophil percentage in CSF was also a negative prognostic factor. 20 
 21 
Abstract 22 
Although long-term outcomes of meningoencephalitis of unknown aetiology 23 
(MUA) in dogs have been evaluated, little is known about short-term survival and 24 
initial response to therapy. The aim of this study was to evaluate possible prognostic 25 
factors for 7-day survival after diagnosis of MUA in dogs.  Medical records were 26 
reviewed for dogs diagnosed with MUA between 2006 and 2015. Previously 27 
described inclusion criteria were used, as well as 7-day survival data for all dogs. A 28 
poor outcome was defined as death within 1 week.  29 
 30 
Of 116 dogs that met inclusion criteria, 30 (26%) died within 7 days of 31 
diagnosis. Assessed variables included age, sex, bodyweight, duration of clinical signs 32 
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and treatment prior to diagnosis, venous blood glucose and lactate levels, white blood 33 
cell count on complete blood count, total nucleated cell count / total protein 34 
concentration / white blood cell differentiation on cerebrospinal fluid (CSF) analysis, 35 
presence of seizures and cluster seizures, mentation at presentation, neuroanatomical 36 
localisation, imaging findings and treatment after diagnosis. Multivariate analysis 37 
identified three variables significantly associated with poor outcome; decreased 38 
mentation at presentation, presence of seizures, and increased percentage of 39 
neutrophils on CSF analysis. Despite initiation of appropriate treatment, more than a 40 
quarter of dogs died within one week of diagnosis of MUA, emphasising the need for 41 
evaluation of short-term prognostic factors. Information from this study could aid 42 
clinical staff to provide owners of affected dogs with prognostic information.  43 
 44 
Keywords: GME; Inflammatory CNS Disease; MRI; MUO; Necrotising encephalitis  45 
 46 
Introduction 47 
Meningoencephalitis of unknown aetiology (MUA) describes all clinically 48 
diagnosed cases of granulomatous meningoencephalitis (GME), necrotising 49 
meningoencephalitis (NME) and necrotising leucoencephalitis (NLE) that lack 50 
histopathological confirmation (Coates and Jeffery, 2014). A clinical diagnosis can be 51 
achieved based on a combination of neurological examination results, magnetic 52 
resonance imaging (MRI) findings and cerebrospinal fluid (CSF) abnormalities 53 
(Coates and Jeffery, 2014). The exact aetiology and pathophysiology of MUA are 54 
currently unknown, but the cornerstone of medical treatment is immunosuppressive 55 
therapy. Several treatment protocols using different immunomodulating drugs, 56 
resulting in different long-term survival times have been reported (Munana and 57 
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Luttgen, 1998; Jung et al., 2007; Coates et al., 2007; Granger et al., 2010; Flegel et 58 
al., 2011; Beckmann et al., 2015; Barnoon et al., 2016).  59 
 60 
Although several studies have focused on long-term survival, little is known 61 
about early survival and initial response to therapy of dogs diagnosed with MUA. The 62 
primary aim of this study was therefore to evaluate early survival and initial response 63 
to immunosuppressive therapy in those dogs. A secondary aim was to investigate 64 
possible prognostic factors for 7-day survival after diagnosis of MUA. It was 65 
hypothesised that a substantial portion of dogs with MUA would succumb in the first 66 
week after diagnosis despite appropriate treatment and monitoring. It was further 67 
hypothesised that specific characteristics of the clinical presentation, neurological 68 
examination, clinical pathology abnormalities, imaging findings and type of treatment 69 
would be associated with 7-day survival in dogs with a presumptive diagnosis of 70 
MUA. 71 
 72 
Materials and methods 73 
Case selection  74 
The electronic medical database of the Small Animal Referral Hospital, Royal 75 
Veterinary College, University of London, was searched between January 2006 and 76 
April 2015 for dogs diagnosed with MUA. Dogs were included based on the criteria 77 
used by Granger et al. (2010), if they had: (1) complete medical records available; (2) 78 
a complete neurological examination performed leading to a focal or multifocal 79 
intracranial neuroanatomical localization; (3) inflammatory CSF analysis; (4) MR 80 
imaging of the brain demonstrating single, multiple or diffuse intra-axial hyperintense 81 
lesions on T2W images; and (5) if 7-day follow-up information was available. Dogs 82 
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with histopathological confirmation of MUA only needed to fulfill inclusion criteria 83 
(1) and (5). In this study, the term MUA was used for all dogs included in the study, 84 
including those with histopathological confirmation of GME, NME or NLE.  85 
 86 
Dogs were excluded if: (1) clinical records or imaging studies were 87 
incomplete or not available for review; (2) dogs were diagnosed with 88 
meningomyelitis without clinical signs of intracranial involvement; (3) no pleocytosis 89 
was found on CSF analysis, with the exception of dogs with signs of raised 90 
intracranial pressure (ICP) on imaging studies, in which case CSF collection was not 91 
performed; and (4) if positive test results were found on serology or PCR examination 92 
for canine distemper virus (CDV), Toxoplasma gondii or Neospora caninum.  93 
 94 
Information retrieved from the medical records included breed, gender, age at 95 
diagnosis, sex, bodyweight, neurological examination results and neuroanatomical 96 
localisation, duration of clinical signs and treatment prior to diagnosis, presence of 97 
concurrent disease, results of complete blood count (CBC) and biochemistry profile, 98 
results of CSF analysis including total nucleated cell count (TNCC), white blood cell 99 
differentiation and total protein (TP) concentration, lactate and glucose concentration 100 
on venous blood gas analysis, treatment received and 7-day survival time.  101 
 102 
Dogs were considered small or medium breed if bodyweight was < 15kg, and 103 
large breed if bodyweight was ≥ 15kg. Mentation was classified as bright alert 104 
responsive (BAR), quiet alert responsive (QAR), obtundation, stupor or coma, 105 
representing decreasing mental status. Possible neuroanatomical localisations 106 
included forebrain, brainstem or cerebellum. Dogs with vestibular signs attributable to 107 
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a brainstem-associated lesion were diagnosed with central vestibular signs. If two or 108 
more CNS regions appeared to be affected on neurological examination, a multifocal 109 
neuroanatomical localization was made, whereas in dogs with only one region 110 
affected a focal neuroanatomical localization was made. MRI was performed under 111 
general anaesthesia with a 1.5T magnet (Intera, Philips Medical Systems). All images 112 
were reviewed by a board certified neurologist (SDD) using Osirix Dicom viewer 113 
(Osirix Foundation, V.5.5.2). The reviewer was blinded to results of the neurological 114 
examination, outcome after 7 days and histopathological findings. Sequences could 115 
vary, but studies included a minimum of T2-weighted (T2W; repetition time (ms); 116 
TR/echo time (ms); TE, 3000/120), T1-weighted (T1W; TR/TE, 400/8) and fluid 117 
attenuating inversion recovery (FLAIR) images of the entire brain in a sagittal, 118 
transverse and dorsal plane. The T1W images were acquired before and after IV 119 
administration of paramagnetic contrast medium (0.1 mg/kg, gadoterate meglumine, 120 
Dotarem, Guerbet). Variables recorded were lesion localisation and distribution, 121 
presence of parenchymal or meningeal contrast enhancement and presence of mass 122 
effect (brain herniation, midline shift, flattening of gyri/sulci). For CSF analysis, site 123 
of collection (cisternal or lumbar), TNCC, TP and cytological differentiation were 124 
recorded. A TNCC < 5 cells/mm
3
 was considered normal. Protein concentration was 125 
considered normal for a cisternal collection if < 0.25 g/L and for a lumbar collection if 126 
< 0.4 g/L (Dewey et al., 2016).  127 
 128 
Treatment and follow-up 129 
For all dogs, the specific treatment protocol was recorded (corticosteroids with 130 
or without cytosine arabinoside). During hospitalisation, all dogs underwent at least 131 
one daily general physical examination and a complete neurological examination by a 132 
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board-certified neurologist or a neurology resident. Neurological examination results 133 
and response to treatment (improvement, deterioration, or static) were systematically 134 
recorded on the kennel sheets. Follow-up information for the first 7 days after 135 
diagnosis was collected from medical records. If dogs were discharged within the first 136 
7 days, medical records were searched for the presence of a re-examination or owner 137 
communication to confirm the dog was alive. Dogs were excluded from the study if 138 
this information was not available. A successful outcome was defined as survival for 139 
at least 7 days after diagnosis of MUA, while an unsuccessful outcome was defined as 140 
death in the first 7 days after diagnosis. For dogs that died in the first week after 141 
diagnosis, information on whether dogs were euthanased at the owner’s request after 142 
diagnosis without treatment, they failed to recover from general anesthesia after MRI, 143 
or they died or were euthanased due to progression of disease after recovery from 144 
general anesthesia was recorded. Dogs that did not survive general anaesthesia or 145 
were euthanased at the owner’s request after diagnosis without treatment were not 146 
included for further analysis. 147 
 148 
Statistical analysis 149 
Outcome was defined as dead or alive 7 days after diagnosis. Data analysis 150 
was performed using a statistical software package (Prism, Graphpad Software). A 151 
Mann-Whitney U test was used to compare age, weight, duration of clinical signs 152 
prior to diagnosis, venous blood glucose and lactate levels, white blood cell (total, 153 
neutrophil and lymphocyte) count on CBC, TNCC/TP/neutrophil percentage in CSF, 154 
between dogs that were dead or alive 1 week after diagnosis. A Fisher’s exact test was 155 
used to compare differences in sex, treatment prior to diagnosis, presence of seizures 156 
and cluster seizures, mentation (BAR, QAR, obtundation, stupor, coma), 157 
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neuroanatomical localisation (multifocal, forebrain, brainstem, central vestibular), 158 
treatment after diagnosis (steroids, cytosine arabinoside, mannitol) and imaging 159 
findings (lesion localisation, meningeal or parenchymal contrast enhancement, mass 160 
effect, brain herniation, flattening gyri/sulci, rostral or caudal transtentorial herniation, 161 
foramen magnum herniation) between dogs that were dead or alive 1 week after 162 
diagnosis.  163 
 164 
A binary response mixed model was carried out using SPSS (Statistical 165 
Package for the Social Sciences v. 21.0.1, SPSS).  The binary response variable was 166 
whether the dog was dead or alive 7 days after diagnosis. Factors found to be 167 
significant at the univariate level were taken forward for multivariate analysis. 168 
Bodyweight, duration of clinical signs, lactate concentration on venous blood gas 169 
analysis, TNCC on CSF analysis and percentage of neutrophils in CSF were modeled 170 
as continuous fixed effects. Mentation was modeled as a categorical fixed effect, and 171 
the presence of seizures, cluster seizures and cytosine arabinoside administration were 172 
modeled as binomial fixed effects. Breed was included as a random effect, with cross 173 
breeds coded plainly as ‘cross breed’ due to unknown parentage. This random effect 174 
took into account the genetic non-independence of multiple members of the same 175 
breed in the study population, and possible demographic and environmental factors. 176 
All models were checked for multicollinearity, identified from inflated standard errors 177 
in the models, and thus avoided. Model fit was assessed using the deviance and 178 
Akaike's information criterion. Numeric variables were expressed as median and 179 
interquartile range. Values of P<0.05 were considered significant. Receiver operating 180 
characteristic (ROC) analysis was performed to examine the performance of the 181 
significant continuous variables on multivariate analysis as an indicator of prognosis, 182 
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by determining the power of the test by measuring the area under the curve (AUC). A 183 
perfect test has an AUC value of 1.0; an AUC of 0.5 means the test performs no better 184 
than chance. 185 
 186 
Results 187 
Signalment 188 
One hundred and sixteen dogs met the inclusion criteria and were included in 189 
the study. Eighty-seven dogs (75%) were small or medium breed and 29 dogs (25%) 190 
were large breed. Median age at presentation was 52.5 months (4 – 146 months) and 191 
median bodyweight was 9.2 kg (1.65 – 94 kg). Fifty dogs (43%) were female, of 192 
which 30 were neutered, compared to 66 males (57%), of which 40 were neutered. 193 
Median duration of clinical signs before diagnosis was 7 days (range 1 – 180 days). 194 
Twenty dogs (17%) were treated with anti-inflammatory doses of glucocorticoids 195 
(doses ranging from 0.5 – 1 mg/kg administered every 12 – 24 h) prior to diagnosis, 196 
with a median duration of 3.5 days (range 1 – 90 days).  197 
 198 
Neurological examination 199 
Mentation was classified as BAR in 30 dogs (26%), QAR in 21 dogs (18%), 200 
obtundation in 59 dogs (51%) and stupor in six dogs (5%). No dogs presented 201 
comatose. Twenty-nine dogs (25%) presented with seizures, of which 20 dogs (69%) 202 
presented with cluster seizures and two dogs (31%) with status epilepticus. Sixty-six 203 
dogs (57%) presented with multifocal neurological signs, 50 dogs (43%) with focal 204 
neurological signs. Of the latter, 39 dogs (78%) presented with focal forebrain signs, 205 
eight dogs (16%) with focal brainstem signs, two dogs (4%) with focal cerebellar 206 
signs, and one dog (2%) with central vestibular signs.  207 
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 208 
Diagnostic findings 209 
Results of CBC and biochemistry profile were available in 97 dogs (84%). 210 
Leucocytosis was present in 13 dogs (13%) and lymphopenia in 32 dogs (33%). 211 
Serology and/or PCR analysis for Toxoplasma gondii, Neospora caninum and canine 212 
distemper virus were available and negative in 82 dogs (71%). Lactate and glucose 213 
concentrations on venous blood gas analysis were available in 49 dogs (42%), 214 
revealing an increased lactate and/or glucose concentration in nine (18%) and 12 215 
(24%) dogs, respectively. CSF analysis was not performed in 20 dogs (17%); it 216 
revealed no abnormalities in three dogs (3%); and a pleocytosis in the remaining 93 217 
dogs (80%). In the three dogs with normal TNCCs, complete necropsy revealed GME 218 
(n=1), NME (n=1) or NLE (n=1). For the dogs with a pleocytosis (n=93), median 219 
TNCC was 80 WBC/mm
3
 (6-2560 WBC/mm
3
). For the dogs that died in the first 220 
week after diagnosis, median percentage of lymphocytes, neutrophils and 221 
monocytes/macrophages was 54%, 5% and 24%, respectively, compared to dogs that 222 
survived the first week after diagnosis, where percentages were 66%, 1% and 23%, 223 
respectively. Pretreatment with glucocorticoids did not significantly influence the 224 
TNCC on CSF analysis (P=0.9116). 225 
 226 
Magnetic resonance imaging revealed a focal lesion in 31 dogs (27%), a 227 
multifocal lesion in 77 dogs (66%) and a diffuse lesion in eight dogs (7%). Mass 228 
effect was seen in 66 dogs (57%), consisting of brain herniation (n=44), midline shift 229 
(n=38) and/or flattening of gyri or sulci (n=51).  230 
 231 
Treatment and outcome 232 
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All but two dogs were alive after MR imaging. Spontaneous breathing did not 233 
return in one dog (1%) after anaesthesia; treatment was initiated with dexamethasone 234 
but the dog was euthanased after 1 h. This dog was excluded from further analysis.  235 
One dog (1%) was not administered further treatment and was euthanased during 236 
general anaesthesia at the owner’s request because of severe neurological signs. The 237 
remaining 114 dogs (98%) were treated with glucocorticoids. Detailed treatment data 238 
were available in 104 cases. Treatment consisted mainly of a single IV dose of 239 
dexamethasone (0.3 – 0.6 mg/kg) within hours of diagnosis, followed by oral 240 
prednisolone therapy (1-2 mg/kg every 12-24 h; n=79), or oral prednisolone therapy 241 
(1-2 mg/kg every 12-24 h, initiated within hours of diagnosis; n=25). Eighty-eight of 242 
114 dogs (85%) received additional treatment with cytosine arabinoside, given as SC 243 
injections (50 mg/m
2 
SC every 12 h for 2 consecutive days) in 69 dogs (78%) and as 244 
an IV constant rate infusion (CRI; 200 mg/m
2
 over 8 h; n=19; 22%). Twenty-seven 245 
dogs (23%) required mannitol (0.5 - 1 g/kg IV over 15-20 mins) administration during 246 
hospitalisation for clinical signs suggestive of raised ICP. This was administered 247 
immediately after intracranial MRI in nine dogs (33%) and during hospitalisation in 248 
the remaining 18 dogs (67%), at a median time after diagnosis of 1 h (range, 1 – 48 249 
h).   250 
 251 
Of the 114 dogs in which treatment was initiated, 84 (74%) survived and 30 252 
dogs (26%) died or were euthanased during the first 7 days after diagnosis. These 253 
dogs died (n=10) or were euthanased (n=20) because of deteriorating neurological 254 
signs. The median survival time (MST) of all deceased dogs was 1 day. Overall, 255 
histopathological confirmation (necropsy) was available in 14 dogs, revealing a 256 
diagnosis of GME (n=9), NME (n=4) or NLE (n=1). Dogs that demonstrated 257 
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neurological improvement did so within a median time of 24 h after diagnosis (range, 258 
12-72 h) and clinical improvement within this time period was significantly 259 
associated with 7-day survival (P<0.0001). 260 
 261 
Factors associated with survival 262 
Univariate analysis revealed that higher bodyweight (P=0.027), shorter 263 
duration of clinical signs prior to diagnosis (P=0.042), decreased mentation at 264 
presentation (P=0.048), the presence of seizures (P=0.002) or cluster seizures 265 
(P=0.005), increased lactate concentration on venous blood gas analysis (P=0.026), 266 
higher TNCC on CSF analysis (P=0.031), higher percentage of neutrophils in CSF 267 
(P=0.0224), administration of IV dexamethasone (P=0.0019), and no administration 268 
of cytosine arabinoside (P=0.012), were all associated with a poor outcome. The 269 
administration of a cytosine arabinoside CRI was significantly associated (P<0.0001) 270 
with a poor outcome compared to the administration of SC cytosine arabinoside. 271 
None of the other evaluated clinical, clinical pathology, or imaging variables were 272 
significantly associated with outcome in this model (Table 1).  273 
 274 
A binary response mixed model was performed on factors found to be 275 
significant at the univariate level.  Three variables were significantly associated with 276 
poor outcome in the final model: percentage of neutrophils in CSF, decreased 277 
mentation at presentation, and a history of seizures (Table 2). Dogs with a higher 278 
percentage of neutrophils were at an increased risk of death at 1 week (mean ± 279 
standard error dead, 14.88 ± 4.01; alive, 6.31 ± 1.40). Dogs with decreased mentation 280 
at presentation were at increased risk of death within 1 week (% dead at 1 week BAR, 281 
20% vs. stupor, 66.7%).  Dogs presented as BAR had an 18.33 increased odds of 282 
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being alive at 1 week compared to those presented in a stuporous state. Finally, dogs 283 
with a history of seizures were at an increased risk of death at 1 week (dead at 1 week 284 
no seizures, 19.5% vs. seizures, 51.7%). Dogs without seizures had 4.20 increased 285 
odds of being alive at 1 week compared to those with seizures. ROC-analysis revealed 286 
that none of the significant continuous variables was able to reliably differentiate 287 
between good and poor short-term outcome in dogs with MUA (Fig. 1).  288 
   289 
Discussion  290 
This study evaluated the prevalence and potential risk factors for 1-week 291 
survival in dogs diagnosed with MUA. Although it was hypothesised that a proportion 292 
of dogs would not survive the first week after obtaining a diagnosis of MUA, a high 293 
proportion (26%) of dogs died within this specific time frame despite the initiation of 294 
appropriate treatment and careful monitoring.  Therefore, the inclusion of this group 295 
of dogs when considering the overall prognosis of dogs with MUA is important. 296 
 297 
It has been reported previously that approximately 15% of dogs diagnosed 298 
with GME died before being treated (Granger et al., 2010), compared to only 1/116 299 
dogs (0.9%) in the present study, where the owner decided to euthanase the dog 300 
without attempting to treat. A recent study reported that 56% of dogs diagnosed and 301 
treated for MUA died or were euthanased with a median survival time of 2 days 302 
(Lowrie et al., 2013), which is over twice the frequency reported here.  303 
 304 
In a recent study by Sharma and Holowaychuk (2015), increased venous 305 
lactate concentrations were a risk factor for non-survival to hospital discharge in dogs 306 
with head trauma. Additionally, hyperglycaemia has been associated with severity of 307 
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injury in cases of head trauma in dogs and cats, but not with outcome (Syring et al., 308 
2001). In the present study, blood glucose and lactate levels were measured on 309 
admission or before MR imaging on standard venous blood gas analysis. No 310 
significant difference was found in blood glucose levels between dogs that did or did 311 
not survive the first week after diagnosis. In the univariate analysis, lactate 312 
concentrations were significantly increased in dogs with a poor outcome, but this 313 
result was not confirmed in the multivariate analysis. As both measurements were 314 
only available for review in approximately 20% of cases, further prospective studies 315 
are required before accurate conclusions can be drawn. 316 
 317 
This study identified some potential risk factors for death in the first 7 days 318 
after diagnosis of MUA, including seizures and/or decreased mentation at 319 
presentation, as has been reported previously (Bateman and Parent, 1999; Coates et 320 
al., 2007). Although it is possible that these dogs represent a group of animals with a 321 
more severe clinical phenotype, we cannot exclude the possibility that the necessity of 322 
administering anti-epileptic drugs in these dogs was associated with increased 323 
sedation and therefore contributed to a further decline of their neurological function. 324 
In contrast to results of a recent study (Lowrie et al., 2013), higher neutrophil 325 
percentage on CSF analysis was significantly associated with increased risk of death 326 
in the first week after a diagnosis of MUA. However, our ROC-curve did not generate 327 
a reliable threshold value with combined high sensitivity and specificity to predict 328 
survival, so the exact neutrophil percentage should not be considered a useful tool for 329 
assessing prognosis in individual animals with MUA. 330 
 331 
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Previous studies have reported that adding another immunosuppressive agent 332 
or radiation therapy to the standard glucocorticoid treatment protocol improved 333 
survival of dogs with MUA (Munana and Luttgen, 1998; Jung et al., 2007; Coates et 334 
al., 2007; Granger et al., 2010; Flegel et al., 2011; Beckmann et al., 2015; Barnoon et 335 
al., 2016) but this was not confirmed in the present study. Surprisingly, treatment with 336 
SC cytosine arabinoside and oral prednisolone were both significantly associated with 337 
better short-term outcomes. This finding is unlikely to be reliable, as clinicians might 338 
have administered IV dexamethasone and an additional CRI of cytosine arabinoside 339 
only to dogs with more severe neurological signs. Additionally, a previous study 340 
(Crook et al., 2013) indicated more favorable pharmacokinetic properties of IV CRI 341 
of cytosine arabinoside compared to SC injections. Neither of these findings could be 342 
confirmed in the multivariate analysis performed in our study.  343 
 344 
This study is limited by its retrospective design. Inclusion criteria were based 345 
on previously reported studies, but were not restrictive. In our study, dogs were 346 
excluded if TNCC on CSF analysis and/or intracranial MRI were within normal 347 
limits. Infectious disease testing was not required for inclusion and the treatment 348 
protocol was not standardised. Medical management was also tailored to individual 349 
needs and therefore some dogs might have received additional medication, such as 350 
anti-epileptic drugs and mannitol. Additionally, dogs received different treatment 351 
protocols prior to admission and diagnosis. Our inclusion criteria might have been 352 
biased towards more severely affected dogs because only dogs with CSF pleocytosis, 353 
dogs with abnormal intracranial imaging and/or dogs with clinical signs of raised ICP 354 
in the absence of CSF analysis were included. Definitive post-mortem diagnosis was 355 
available in almost half of the dogs (14/30; 47%) that died within 1 week after 356 
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hospital diagnosis. This might also suggest a bias towards the inclusion of more 357 
severely affected cases, as dogs that died or were euthanased in a hospital 358 
environment might have been more likely to undergo post-mortem examination.  359 
 360 
Conclusions 361 
Twenty-six percent of dogs diagnosed with MUA in this study died within 1 362 
week after diagnosis, emphasising the need to evaluate of short-term prognostic 363 
factors. The presence of decreased mentation at time of presentation, seizures, and 364 
increased neutrophil percentage in the CSF were significantly associated with death 365 
within 7 days after diagnosis. The results of this study could be important when 366 
considering the overall prognosis of dogs with MUA and managing expectations of 367 
owners and hospital staff.  368 
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Figure legend 474 
 475 
Fig. 1. Receiver operating characteristic (ROC) curve for neutrophil percentage in 476 
cerebrospinal fluid. The area under the curve was 0.63, indicating that this continuous 477 
variable has no clinical use in differentiating between good and poor outcome within 478 
7 days after diagnosis. Consequently, no reliable threshold values with combined high 479 
sensitivity and specificity could be identified to differentiate between both dogs with a 480 
good and poor outcome. 481 
 482 
Table 1. Results after univariate analysis. Values are numbers with respective 483 
percentages or median values with respective interquartile ranges. Dogs (n=2) that did 484 
not recover from the general anesthesia for MR imaging, were not included in the 485 
analysis considering treatment.  486 
Variable Death ≤7 days  
(n=32) 
Alive after 7 days 
(n=82) 
P  
Signalment       
   Age (months) 55 (7 - 35) 50.5 (4 - 146) 0.987 
   Male 21 (66%) 45 (54%) 0.521 
   Female 11 (34%) 39 (46%) 0.521 
   Bodyweight (kg) 10.25 (3 – 94) 8.9 (1.65 – 54.9) 0.027 a 
Duration of clinical signs 
prior to diagnosis (days) 
6 (1 – 60) 8 (1 – 180) 0.042 a 
Treatment with 
glucocorticosteroids prior to 
diagnosis (days) 
1.5 (1 – 9) 3 (1 – 48) 0.061 
Clinical signs       
   Seizures 15 (47%) 14 (17%) 0.002
 a
 
   Cluster seizures 11 (34%) 9 (11%) 0.005
 a
 
Neuroanatomical 
localisation 
      
   Forebrain 24 (75%) 56 (67%) 0.502 
   Brainstem 21 (66%) 50 (60%) 0.671 
   Central vestibular 8 (25%) 23 (27%) 1.000 
   Abnormal mentation 7 (22%) 23 (27%) 0.362 
   Stuporous 4 (13%) 2 (2%) 0.048
 a
 
Complete blood count       
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Variable Death ≤7 days  
(n=32) 
Alive after 7 days 
(n=82) 
P  
   White blood cells (.10
9
/l) 13.10 (3.54 – 25.1) 9.97 (4.6 – 32.8) 0.103 
   Neutrophils (.10
9
/l) 10.16 (2.4 – 23.9) 7.2 (3 – 28.3) 0.267 
   Lymphocytes (.10
9
/l) 1.1 (0.1 – 3.5) 1.3 (0.17 – 3.6) 0.177 
   Lymphopenia 11 (34%) 21 (25%) 0.217 
Venous blood gas       
   Lactate (mmol/l) 2.1 (0.5 – 5.5) 1.4 (0.4 – 5,6) 0.026 a 
   Glucose (mmol/l) 6.3 (4 – 7.9) 5.69 (3.2 – 11.1) 0.100 
CSF analysis       
   TNCC (WBC/mm
3
) 364 (1 – 2220) 66 (5 - 2560) 0.031 a 
   Total protein (g/l) 0.79 (0.1 – 5.56) 0.46 (0.11 – 8.5) 0.410 
   Not performed because 
signs of raised ICP 
7 (22%) 13 (15%) 0.289 
    Lymphocyte percentage 54 (2 – 97) 66 (1 – 98)  0.087 
    Neutrophil percentage 5 (0 – 64) 1 (0 – 61) 0.022 a 
    Monocyte/macrophage 
percentage 
24 (3 – 87) 23 (0 – 92) 0.981 
MRI findings       
   Focal lesion 7 (22%) 24 (29%) 0.635 
   Multifocal lesion 22 (69%) 55 (65%) 0.635 
   Diffuse lesion 3 (9%) 5 (6%) 0.386 
   Forebrain localisation 26 (81%) 63 (75%) 0.327 
   Brainstem localisation 16 (50%) 45 (54%) 0.445 
   Cerebellum localisation 4 (13%) 17 (20%) 0.248 
   Mass effect 16 (50%) 50 (60%) 0.405 
      Brain herniation 8 (25%) 36 (43%) 0.058 
         Caudal transtentorial     
herniation 
7 (22%) 36 (43%) 0.053 
         Foramen magnum 
herniation 
8 (25%) 22 (26%) 0.549 
      Midline shift 11 (34%) 27 (32%) 0.492 
      Flattening gyri/sulci 15 (47%) 36 (43%) 0.427 
   Contrast enhancement       
      Meningeal contrast 
enhancement 
24 (75%) 54 (64%) 0.191 
      Parenchymal contrast 
enhancement 
20 (63%) 60 (71%) 0.239 
Treatment         
   Dexamethasone 27 (84%) 52 (62%) 0.002
 a
 
   Prednisolone 1 (6%) 24 (28%) 0.002
 a
 
   Cytosine arabinoside 19 (60%) 69 (82%) 0.012
 a
 
   Cytosine arabinoside CRI 12 (20%) 7 (10%) < 0.001
 a
 
   Cytosine arabinoside SC 9 (47%) 60 (87%) < 0.001
 a
 
   Mannitol 8 (25%) 19 (23%) 0.806 
Improvement after treatment 4 (13%) 82 (97%) <0.001
 a
 
   Time from diagnosis to 2 (1 – 48) 2 (1 – 72) 0.153 
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Variable Death ≤7 days  
(n=32) 
Alive after 7 days 
(n=82) 
P  
treatment with 
corticosteroids (h) 
CSF, cerebrospinal fluid; TNCC, total nucleated cell count; WBC, white blood cells; 487 
ICP, intracranial pressure; CRI, constant rate infusion 488 
a
 P<0.05 489 
 490 
Table 2. Results of binary response mixed model analysis of key predictors on the 491 
risk of death after 1 week (reference category: dead at 1 week).  492 
Variable Sub 
category 
SE 
(coefficient) 
OR (95% CI 
OR) 
t P 
Neutrophils - 0.96 0.093-0.99 -2.21 0.030
 a
 
Mentation 
BAR 18.33 1.39-241.33 2.24 0.027
 a
 
QAR 4.77 0.41-55.00 1.27 0.208 
Obtundation 6.40 0.58-69.72 1.55 0.126 
Stupor Reference category 
Seizures 
No 4.20 1.08-16.37 2.10 0.039
 a
 
Yes Reference category 
 493 
OR, odds ratio; CI, confidence interval; SE, standard error; BAR, bright alert 494 
responsive; QAR, quiet alert responsive.  495 
a 
P<0.05  496 
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